Top

Published in:

01-08-2014 | Leading Article

New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment

Authors: Sarah Zimner-Rapuch, Nicolas Janus, Gilbert Deray, Vincent Launay-Vacher

Published in: Drugs | Issue 12/2014

Abstract

Hepatitis C virus (HCV) is a major public health issue because infection may lead to liver failure, cirrhosis and hepatocellular carcinoma. In patients with renal dysfunction, hepatitis C can also worsen the underlying renal disease. Treating HCV infection is thus mandatory in this population. New therapies for hepatitis C have recently been developed, and some have been launched. Most of them are used in combination with the current standard of care, ribavirin and pegylated interferon alfa. Some of them can be used in regimens without ribavirin and/or pegylated interferon. However, few data are available on dosage adjustment for renal function in patients receiving these very new drugs. We reviewed the literature on this subject and gathered information, although scarce, to propose guidelines for using these drugs in patients with chronic kidney disease.

Kamar N, Alric L, Izopet J, Rostaing L. Hepatitis C virus and kidney disease. Clin Res Hepatol Gastroenterol. 2013;37:328–33.PubMedCrossRef

Vallet-Pichard A, Pol S. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol. 2013;37:340–6.PubMedCrossRef

Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14:3270–7.PubMedCrossRef

Brennan BJ, Wang K, Blotner S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57:6097–105.PubMedCentralPubMedCrossRef

Tseng P-L, Chen T-C, Chien Y-S, et al. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis. 2013;62:789–95.PubMedCrossRef

Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669–89 (quiz 690).PubMedCrossRef

Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol Adv Appl. 2014;6:1–17.

Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail. Hepatology. 2011;54:3–5.PubMedCrossRef

Van Heeswijk R. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir. Available at http://download.journals.elsevierhealth.com/pdfs/journals/0168-8278/PIIS0168827811612476.pdf. Accessed 25 Feb 2014.

10.

Garg V, Kauffman RS, Beaumont M, van Heeswijk RPG. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17:1211–21.PubMedCrossRef

11.

Dumortier J, Guillaud O, Gagnieu M-C, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56:146–9.PubMedCrossRef

12.

Basu PP, Siriki R, Shah NJ, et al. Telaprevir with adjusted dose of ribavirin in naïve CHC-G1: efficacy and treatment in CHC in hemodialysis population. In: TARGET C (RCT) 48th annual meeting of the european association for the study of the liver, April 24–28, 2013. Amsterdam, Netherlands; 2013. Abstract 67.

13.

Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20–7.PubMedCrossRef

14.

Treitel M, Marbury T, Preston RA, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51:619–28.PubMedCrossRef

15.

Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology. 2014;59:46–8.PubMedCrossRef

16.

Loustaud-Ratti V, Carrier P, Vong C, Essig M. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014;59(6):2426.

17.

Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907–17.PubMedCentralPubMedCrossRef

18.

Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int. 2013;33(Suppl 1):80–4.PubMedCrossRef

19.

Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2014. doi:10.3851/IMP2773.

20.

Garimella T, He B, Luo W-L, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. In: 64th annual meeting of the american association for the study of liver diseases Nov 1–5, 2013. Washington, DC; 2013. Abstract.

21.

Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. In: 47th annual meeting of the european association for the study of the liver (EASL), April 18–22, 2012. Barcelona, Spain; 2012. Abstract 1101.

22.

Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Invest Drugs. 2013;22:527–36.CrossRef

23.

Clinical trials.gov. Sofosbuvir plus ribavirin in subjects with HCV infection and renal insufficiency. Available at http://clinicaltrials.gov/ct2/show/NCT01958281. Accessed 28 Feb 2014.

24.

Clinical trials.gov. Pharmacokinetic and safety study of daclatasvir in patients with renal impairment. Available at http://clinicaltrials.gov/ct2/show/NCT01830205?term=daclatasvir+and+kidney&rank=1. Accessed 28 Feb 2014.

25.

Garimella T, Wang R, Luo W-L, et al. The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, 19–21 May 2014. Available at http://www.natap.org/2014/Pharm/Pharm_18.htm. Accessed 10 July 2014.

26.

Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Invest Drugs. 2014;23:561–71.CrossRef

27.

Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.PubMedCrossRef

28.

Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.PubMedCrossRef

29.

Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.PubMedCrossRef

Title: New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment
Authors: Sarah Zimner-Rapuch
Nicolas Janus
Gilbert Deray
Vincent Launay-Vacher
Publication date: 01-08-2014
Publisher: Springer International Publishing
Published in: Drugs / Issue 12/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-014-0268-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Asthma Therapy and Its Effect on Airway Remodelling

Nemonoxacin: First Global Approval

Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy